

EIT Health Accelerator

A pan-European catalyst for life science innovation.
From labs to patient

TESTIMONIALS



Co-funded by the
European Union



Partnership with European Investment Fund since 2020

“Public resources can only go so far in supporting key sectors of the economy like life sciences. That’s why successfully mobilising private actors to boost investments in this field is so important. With the VCoE, we are seeing exactly this: an innovative approach that creates value for corporates, start-ups and investors alike, and nourishes the healthcare sector with new opportunities. It’s about creating bridges and fostering a dynamic, effervescent investment ecosystem, ultimately for the benefit of patients everywhere. We are proud of the collaboration with EIT Health that has brought to life the VCoE, and facilitated more than 140 investments into companies in the life sciences sector, and look forward to developing similar models in other fields of our work.” **Marjut Falkstedt, EIF Chief Executive**



Stefan Dobrev, Chairperson of EIT Governing Board

As Chairman of the European Institute of Innovation and Technology (EIT) from the 1st of July 2024, I am privileged to witness and champion the profound impact of the EIT Health Accelerator programme - a driving force in addressing Europe's most pressing healthcare challenges.

Since its establishment in 2016, the Accelerator has been a pioneer at the forefront of EIT Health, tackling these critical health issues head-on, solidifying its position as a shining beacon of innovation within our network of Knowledge and Innovation Communities (KICs).

The Accelerator bridges the gap between research and real-world applications, propelling groundbreaking healthcare solutions from labs to patients across Europe. As a transformative public-private platform, it facilitates start-up creation, growth and value generation, guiding enterprises from lab to market. The Accelerator fosters synergies across the healthcare ecosystem, offering tailored support to catalyse innovation and drive impact.

In lockstep with European institutions, the EIT Health Accelerator spearheads landmark initiatives in the life sciences and health domains, positioning itself as a strategic implementation partner for the European Commission's visionary programmes. Its far-reaching impact enhances the quality of life for Europeans, transcending boundaries to encompass the digitalization of healthcare, bolstering and greening bioproduction capabilities, and ensuring the equitable realisation of personalised and precision medicine at scale.

Through its partnership model, the Accelerator fosters connections and cultivates collaboration across the entire healthcare spectrum. Serving as the single-entry point for startups in Healthtech into Europe's rich innovation ecosystem, it harnesses the collective strengths of public and private stakeholders, driving positive societal impact.

I take immense pride in the remarkable achievements of the EIT Health Accelerator programme, and I eagerly anticipate witnessing their continued success in driving healthcare innovation accelerating a healthier future for Europe and beyond.



Ontario Brain Institute



EIT Health e.V.
Mies-van-der-Rohe-Str 1C
80807 Munich
Germany

Attn: Isaac Middelmann, EIT Health Accelerator Director - Strategic Fundraising
Watt-Biopark, 8 Rue Jean Antoine de Baif, 75013 Paris

Re: Letter of support for EIT Health's application to the Galien Prize

The Ontario Brain Institute (OBI) is pleased to write this letter of support to EIT Health in support of their submission to the Galien Prize committee.

OBI is a leading organization at the forefront of neuroscience research and innovation, committed to supporting innovative research, fostering collaboration, and translating scientific discoveries into tangible improvements in patient care and quality of life. Our mandate is realized through our collaborative 'team science' approach between researchers, clinicians, industry, patients, and their advocates to foster discovery and deliver innovative products and services that improve the lives of those living with brain disorders.

This collaborative approach also extends to global partners such as EIT health. The OBI became an EIT Health partner in 2023 to bolster its access to the European Life Science ecosystem as thanks to the wide range of entities that EIT Health contains within its network. In so doing, we've built a concrete transatlantic programme supporting the internationalization of European neurotechs and mental health start-ups into the North American market, as well as to support Canadian start-ups wishing to access the European ecosystem of investors, corporates, research centers, KOLs and others.

This type of focused, win-win initiative is exciting as it leverages our respective ecosystems and helps break down the many geographic, thematic, and other silos that can slow the development of innovation, in turn delaying the potential benefits for patients.

Through our partnership with EIT Health, OBI has gained access to a vibrant ecosystem, and we look forward to what we can build together next and wholeheartedly support their submission to the Galien Prize 2024!

Best regards,

John Clarkson
SVP and COO
Ontario Brain Institute



Werfen - Louise Warme, Head of We Venture Capital

"Joining the VCoE was a great way for We Venture Capital to access a European network of likeminded investors operating in the life science space with high competence in the field. Through those relationships, we have been able to explore conditions for coinvestment, discuss changes in the investment landscape and exchange dealflow. As We venture Capital launched this year, it was incredibly valuable for us to access the community and the invaluable support from the EIT health team."



Ysios Capital - Raúl Martín-Ruiz, Partner

“Ysios Capital joined the VCoE community as the first VC member, and since then we have been actively engaged with the program. The financial contribution of the SDUF Healthcare compartment to our third fund allowed us to increase our commitments to European portfolio companies, and helped us to enlarge our network with other VC firms and corporates that are members of the program. Moreover, it also gave us the possibility of evaluating curated investment opportunities coming from EIT Health. Our portfolio companies are also benefiting from our participation in the program through our networking activities with other VCoE members as potential co-investors and partners. The program has been great so far, and we hope that it will remain in force as a very relevant initiative for supporting the European life sciences ecosystem”



Startup EIT Health-supported start-up Ochre Bio signs \$1BN+ deal with Boehringer Ingelheim

“Chronic liver disease is now the third leading cause of premature death in much of the developed world. We are excited to work with the R&D leaders at Boehringer Ingelheim to advance medicines for this important and under-treated disease,” said Jack O’Meara, Co-Founder and CEO at Ochre Bio. “Participating on EIT Health’s Gold Track programme gave us direct access to industry leaders who could advise and open doors for us. The people involved in Gold Track are top drawer and we have remained in touch with many of them until today.”



EIT Health-supported ABLE Human Motion receives CE mark

Alfons Carnicero, Co-Founder and CEO, ABLE Human Motion, said: *“EIT Health has supported ABLE with multiple instruments along the journey, providing access to early-stage funding, mentoring from healthcare experts from all over the value chain and a network of partners, including top-notch hospitals, universities and businesses around Europe. Thanks to them, the clinical trials of the ABLE Exoskeleton were conducted in two leading neurorehabilitation hospitals in Germany and Spain, which has given us a lot of credibility and recognition in the field.”*



EIT Health supported startup inHEART secures \$11M to optimise cardiac care

Todor Jeliaskov, Chairman and CEO of inHEART said “At inHEART, we are committed to addressing the needs of cardiac patients through early screening, disease detection, and advanced therapeutic support. We are proud to collaborate with EIT Health, which helps us improve our AI capabilities and gather additional clinical evidence. It’s exciting for EIT Health and inHEART to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.”



Ablevia - Christof Paparella & Oskar Smrzka Co-founders

“EIT Health provided us with brilliant support, including access to a network of experts and investors, top-notch mentoring with in-depth strategic advice, and much needed exchange with sparring partners. EIT Health were the right partners at the best moment of our company's development. [...] EIT Health features a multidisciplinary team of smart and open-minded individuals covering essential key areas needed for establishing contacts to the pharma and biotech industry, and strategic investors. [...] Through the VCoE programme we gained easy access to an exclusive community of selected funds and private investors. We are grateful to be part of such an initiative, which makes Europe an attractive place to found new companies and turn disruptive ideas into reality.”

